Amphastar Pharmaceuticals, Inc.

NASDAQ:AMPH

Drug Manufacturers - Specialty & Generic

Healthcare
$29.71 -1.60%

-$0.31 today

Market cap
$1.27B
Beta
0.90
P/E (TTM)
10.9
EPS (TTM)
$1.75
52W Low $16.65High $31.26

Volume 0.53M

Average 0.59M

AMPH Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Amphastar Pharmaceuticals, Inc.NASDAQ: AMPH

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 41.1%

Gross margin was 41.1% in Q1 FY2026, down 8.9 pp from a year earlier. On a trailing-twelve-month basis it was 47.3%, down 3.3 pp year over year. Over 3 fiscal years it narrowed by 0.4 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
41.1%-5.7 pp QoQ
Last fiscal yearDec 2025
49.5%-1.6 pp YoY
LTMMar 2026
47.3%-3.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-8.9 pp——
1 year-1.6 pp——
3 years-0.4 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
49.5%
Year-over-year change
-1.6pp

Gross Margin vs competitors

How AMPH compares with its peers on the latest reported figures

  • AMPH's LTM Mar 2026 gross margin of 47.3% is the 6th highest of the 8 companies compared; the peer median is 52.5%.
  • Its year-over-year change of -3.3 pp is the 6th highest of 8, against a peer median of +1.1 pp.
  • Over three fiscal years its change of -0.4 pp compares with a peer median of -0.3 pp.
AMPH Competitors Peer median
Gross Margin for AMPH and competitors
Company Period LTM level YoY 3-year change
BHCBausch Health Companies Inc.LTM Jun 202671.8% +1.1 pp-0.3 pp
COLLCollegium Pharmaceutical, Inc.LTM Mar 202660.7% +3.0 pp+14.2 pp
ETONEton Pharmaceuticals, Inc.LTM Mar 202654.8% -3.7 pp-13.9 pp
TEVATeva Pharmaceutical Industries LimitedLTM Jun 202652.5% +2.9 pp+5.1 pp
RDYDr. Reddy's Laboratories LimitedLTM Sep 202649.5% -7.0 pp-3.9 pp
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202647.3% -3.3 pp-0.4 pp
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 202639.3% +1.7 pp+1.9 pp
VTRSViatris Inc.LTM Jun 202634.8% -1.8 pp-4.9 pp
Peer median (excluding AMPH) 52.5%+1.1 pp-0.3 pp

Competitors are the stored peer set for AMPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue437.77M498.99M644.4M731.97M719.89M
Cost of Revenue238.03M250.13M293.27M358.11M363.83M
Gross Profit199.74M248.86M351.12M373.86M356.06M
Gross Margin45.6%49.9%54.5%51.1%49.5%
Research & Development60.93M74.77M73.74M73.91M85.84M
Selling, General & Admin68.92M66.59M80.39M94.52M129.81M
Operating Expenses129.85M141.36M154.13M168.44M215.65M
Depreciation & Amortization26.53M28.28M41.78M57.21M63.2M
EBITDA111.56M146.16M240.29M277.31M212.31M
EBITDA Margin25.5%29.3%37.3%37.9%29.5%
Operating Income69.89M107.5M196.99M205.42M140.4M
Operating Margin16.0%21.5%30.6%28.1%19.5%
Interest Income601K1.32M5.46M10.61M8.68M
Interest Expense885K1.85M27.16M30.34M25.48M
Other Income / Expenses14.04M7.37M(27.61M)(16.23M)(16.78M)
Income Before Tax83.93M114.86M169.38M189.19M123.62M
Pre-Tax Margin19.2%23.0%26.3%25.8%17.2%
Income Tax Expense20.63M23.48M31.83M29.67M25.53M
Net Income62.12M91.39M137.55M159.52M98.09M
Net Margin14.2%18.3%21.3%21.8%13.6%
EPS (Basic)1.301.882.853.292.10
EPS (Diluted)1.251.742.603.062.03
Weighted Avg Shares47.78M48.55M48.27M48.43M46.74M
Weighted Avg Shares (Diluted)49.78M52.43M53M52.06M48.22M

Amphastar Pharmaceuticals, Inc.

NASDAQ:AMPH

Intrinsic Alpha fair value

Locked

Current Price

$29.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.